Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Pfizer in advanced talks to buy Global Blood Therapeutics for $5 billion - WSJ

Stock Markets Aug 05, 2022 12:55PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: People pose with syringe with needle in front of displayed Pfizer logo in this illustration taken, December 11, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

(Reuters) -Pfizer Inc is in advanced talks to buy drugmaker Global Blood Therapeutics (NASDAQ:GBT) for about $5 billion, the Wall Street Journal reported on Friday, citing people familiar with the matter.

Pfizer (NYSE:PFE) is aiming to seal a deal in the coming days, but other suitors are still in the mix, the report said.

Shares of Global Blood, which makes a blood disorder drug called Oxbryta, soared 44% in afternoon trade to a two-year high. The company had a market capitalization of $3.12 billion, as of Thursday's closing price.

Pfizer declined to comment on the report, while a Global Blood spokesperson said it does not "comment on market rumors or speculation".

New York-based Pfizer, flush with cash from its COVID-19 vaccine, is on the lookout for acquisitions that could bring in billions in annual sales by the end of the decade.

Its $11.6 billion deal for migraine drug maker Biohaven Pharmaceutical Holding in May was the latest in a string of acquisitions including Trillium Therapeutics (NASDAQ:TRIL) and Arena Pharmaceuticals over recent years.

Global Blood's Oxbryta was approved in the United States for the treatment of sickle cell disease among patients 12 years and older in 2019. In December, the oral drug received approval for the treatment of the condition in younger patients as well.

Sales of the drug rose more than 50% to $194.7 million in 2021.

Biotech dealmaking activity has picked up again in recent months after a bleak start to the year, when a dearth of major acquisitions and clinical-stage drug failures dampened investor sentiment and squeezed funding.

On Thursday, Amgen Inc (NASDAQ:AMGN) agreed to buy drugmaker ChemoCentryx (NASDAQ:CCXI) Inc for $3.7 billion to gain access to a potential blockbuster treatment for inflammatory disorders.

Pfizer in advanced talks to buy Global Blood Therapeutics for $5 billion - WSJ
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (2)
Arub Baji
Arub Baji Aug 05, 2022 4:09PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I wonder how many shares Pelosi and Fauci have in Pfizer ...
Arub Baji
Arub Baji Aug 05, 2022 4:08PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
make em sick with the covid shot then provide something to take the 'edge' off the endless symptoms for those that survive the experimental shot ... good business plan.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email